Amae Health Featured on Advancements with Ted Danson

Spravato success rate figures are easy to find and hard to compare. In the trial that supported its FDA approval, 69.3% of people who finished 4 weeks of Spravato with a new antidepressant had responded, and 52.5% were in remission. A study of routine care in Italy found 64.2% response and 40.6% remission at 3 months. The numbers answer slightly different questions, but they agree on the essentials: Spravato helps many people with treatment-resistant depression, response is more common than remission, and no single percentage tells the whole story.

Spravato also leaves a real share of people without enough relief.

Spravato is the brand name for esketamine, a nasal spray FDA-approved for treatment-resistant depression: depression that hasn't responded adequately to at least two antidepressants, each given at a proper dose for long enough.

What "Success" Means: Response vs. Remission

Nearly every Spravato statistic comes from one yardstick, the Montgomery-Åsberg Depression Rating Scale (MADRS). It's a 10-item interview a clinician scores from 0 to 60, where higher means more severe, and people entering Spravato's main approval trial averaged about 37. Two thresholds turn that score into a success rate:

• Response means the MADRS score has fallen by at least half from where it started.
• Remission means the score has dropped to 12 or lower, the cutoff the Spravato trials used.

The distance between the two is wide. Someone who starts at 38 and falls to 19 counts as a responder and may still have symptoms that get in the way of work, sleep, or relationships. Remission is the fuller recovery and the harder bar, so every remission figure below sits under its response figure.

Spravato's Success Rate in the Trial Behind Its Approval

The short-term trial that supported FDA approval was TRANSFORM-2, published in The American Journal of Psychiatry in 2019. Researchers at 39 outpatient centers enrolled adults with moderate to severe depression who hadn't responded to at least two antidepressants in their current episode. Everyone switched to a new oral antidepressant. One group also received Spravato, 56 or 84 mg twice a week, and the other a placebo spray. Of 227 people randomized, 197 finished the 4-week double-blind phase, and MADRS scores in the Spravato group fell 4 points more, on average.

The European Medicines Agency's review of the trial data translates that into response and remission:

Look first at the comparison group: more than half of the people who started a new antidepressant with a placebo spray also responded. The trial's finding is the gap. Among people who completed 4 weeks, adding Spravato meant about 17 more responders and 21 more remitters in every 100.

The counting method matters too, and it explains much of the inconsistency online. Figures near 69% count only people who finished. Figures near 63% for response, or 48% for remission, carry forward the last score of everyone who stopped early.

Real-World Success Rates

Trials select their patients carefully and follow them for weeks. Routine care is messier, which is what makes REAL-ESK useful. That 2022 study, published in the Journal of Affective Disorders, reviewed the medical records of 116 people with treatment-resistant depression treated with Spravato at several Italian mental health services, with assessments at 1 and 3 months.

By 3 months, 64.2% had responded and 40.6% were in remission, and both rates had climbed sharply between the first month and the third. The authors called that later response one of the study's novel findings. They also found no difference in effectiveness between people with other psychiatric conditions and people without them.

Lining those numbers up against TRANSFORM-2 doesn't work cleanly. REAL-ESK had no placebo or comparison group, everyone knew they were receiving Spravato, ratings weren't checked for consistency across centers, and 3 months is a different finish line from 4 weeks. It's encouraging evidence from everyday practice, not a controlled measure of effect.

Who Spravato Is Approved and Studied For

Spravato has two FDA-approved uses, built on separate trials, according to its prescribing information:

• Treatment-resistant depression in adults, on its own or with an oral antidepressant. The original 2019 approval required an oral antidepressant alongside it; standalone use was added in January 2025.
• Depression with acute suicidal thoughts or behavior, in adults with major depressive disorder, given alongside an oral antidepressant to treat the depressive symptoms.

The second use came from trials of a different group: adults with moderate to severe depression and active suicidal thoughts with intent, all of whom began with an inpatient psychiatric stay and standard care, and 63% of whom had attempted suicide before. Those results shouldn't be mixed with the treatment-resistant depression results.

The label is explicit about one boundary. Spravato hasn't been shown to prevent suicide or to reduce suicidal thoughts or behavior, and it doesn't replace hospitalization when that's needed, even if someone feels better after the first dose. It isn't approved for children. If suicidal thoughts are part of what you're living with right now, care for suicidal thoughts comes first, and 988 answers calls and texts at any hour.

How Fast Results Typically Appear

Spravato's reputation for speed comes from the first day. In TRANSFORM-2, most of the difference from placebo was already visible at 24 hours, the label reports; both groups kept improving through day 28, and the gap held steady rather than widening. The monotherapy trial behind the 2025 approval showed an effect at about 24 hours that lasted through day 28. In the suicidal-thoughts trials, the difference appeared as early as 4 hours.

Early movement isn't the same as response. In TRANSFORM-2, only 7.9% of people on Spravato had a response that began by day 2 and held through day 28, compared with 4.6% on placebo spray, a difference that wasn't statistically significant in the EMA review. The label calls for judging benefit at the end of the 4-week induction phase, after which sessions drop from twice a week to weekly.

And as REAL-ESK suggests, for some people even 4 weeks is early.

What Affects Individual Success

Research points to a handful of factors linked to outcomes, none of them a forecast for any one person:

• Time on treatment. Benefit is formally assessed after the 4-week induction phase, and in REAL-ESK, many responses and remissions arrived between the first and third month.
• Continuing after a good response. In a maintenance study described in the label, people in stable remission who kept taking Spravato went significantly longer before relapsing than people switched to a placebo spray, and the same held for people in stable response.
• Age. The evidence is weaker in older adults. In a separate short-term trial of adults 65 and older, response at day 28 was 27.0% with Spravato versus 13.3% with placebo spray, and the trial's main measure narrowly missed statistical significance, per the EMA review.
• Other psychiatric conditions. REAL-ESK found people with additional psychiatric diagnoses did as well as people without them.
• With or without an oral antidepressant. Spravato has shown benefit both ways, but no trial in the label compared the two head to head.

Limits and Risks

The same data show where Spravato falls short.

• Many people don't reach remission. Nearly half of the people who completed TRANSFORM-2 on Spravato weren't in remission at day 28, and in REAL-ESK, about six in 10 weren't in remission at 3 months.
• Not every trial was positive. Of the three short-term trials submitted for approval, only TRANSFORM-2 met its main goal. A fixed-dose trial in adults and the trial in older adults both fell short of statistical significance, according to the EMA review.
• It carries a boxed warning for sedation, dissociation, breathing problems (respiratory depression), and misuse or abuse, plus the risk of suicidal thoughts and behaviors that antidepressants carry for children and young adults. Sedation showed up in 48% to 61% of trial participants on Spravato, and dissociation, a sense of detachment that can warp time, space, or surroundings, in 61% to 84%.

Those risks shape how Spravato is given. It's only available through a restricted program called the Spravato REMS. You use the spray yourself under supervision in a certified healthcare setting, your blood pressure is checked before and after, and you're monitored for at least 2 hours before you're cleared to leave. Driving is off-limits until the next day, after a night of restful sleep. People with certain blood vessel problems, including an aneurysm, an abnormal connection between arteries and veins, or past bleeding in the brain, can't take it at all.

Talking to a Psychiatrist About Your Options

A Spravato success rate is a group statistic. It shows that Spravato helps a substantial share of people with treatment-resistant depression and that remission is harder to reach than response. It can't tell you what will happen for you. That depends on your diagnosis, what you've tried and for how long, your medical history, and the rest of your care.

We don't offer Spravato at Amae. Major depressive disorder is among the conditions our clinics specialize in, and when it hasn't eased with medication, our psychiatrists treat it within our integrated care model, which puts psychiatry, medication management, therapy, and primary care on one team. TMS therapy runs at three of our clinics: Los Angeles, Los Altos, and San Mateo. Our comparison of TMS, ketamine, and Spravato and our look at TMS success rates lay out how those options differ. To go over your history with someone who can see all of it, schedule an evaluation with an Amae psychiatrist. Anyone in immediate danger should call 911.

Frequently Asked Questions

What is Spravato's success rate in clinical trials?

In TRANSFORM-2, the short-term trial behind FDA approval, 69.3% of people who completed 4 weeks of Spravato plus a new antidepressant responded and 52.5% reached remission, versus 52.0% and 31.0% with a placebo spray plus a new antidepressant. Counting people who left early, remission was 48.2% versus 30.3%.

Does Spravato work better in real-world use than in trials?

The figures look similar, but they can't be compared directly. REAL-ESK, a study of 116 people treated in routine care in Italy, found 64.2% response and 40.6% remission at 3 months, with no placebo group and a longer follow-up than the 4-week trials.

How fast does Spravato start working?

Average scores often pull ahead of placebo within 24 hours, and in trials of people with suicidal thoughts, within 4 hours. A lasting response that early is uncommon, so benefit is judged after the 4-week induction phase, and some people improve later still.

Does Spravato work for everyone?

No. In TRANSFORM-2, nearly a third of people who completed treatment didn't respond, and nearly half didn't reach remission. Two other short-term trials, including one in adults 65 and older, didn't reach statistical significance on their main measure.

What happens if Spravato doesn't work for me?

A psychiatrist looks at the whole picture again: the diagnosis, whether treatment ran long enough, other medications, and other conditions. Next steps might include a different medication strategy, adding or changing therapy, or another treatment for treatment-resistant depression, such as TMS or ECT.

Is Spravato's success rate different for suicidal depression versus treatment-resistant depression?

Yes, and the two shouldn't be blended. The suicidal-thoughts trials measured average score changes 24 hours after the first dose in hospitalized adults receiving standard care. Spravato lowered depression scores more than placebo, but it didn't improve a rating of suicidality more than placebo, and it hasn't been shown to reduce suicidal thoughts.

Citations

1. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. The American Journal of Psychiatry. 2019;176(6):428-438. https://pubmed.ncbi.nlm.nih.gov/31109201/ (Tier 1)
2. European Medicines Agency. Spravato: EPAR public assessment report (EMA/614876/2019). 2019. https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf (Tier 2, regulatory review)
3. Martinotti G, Vita A, Fagiolini A, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). Journal of Affective Disorders. 2022;319:646-654. https://pubmed.ncbi.nlm.nih.gov/36167246/ (Tier 1)
4. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised April 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf (Tier 2)
5. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

Social media can enhance connection, increase self-esteem, and improve a sense of belonging. But it can also lead to emotional fatigue, self-comparison, and loneliness. These are just a few of the positive and negative effects of social media - and how we experience them often depends on how we use these platforms.

This article explores the negative and positive effects of social media - and how mindful use can help protect mental health. Whether you scroll for comfort or out of habit, understanding the impact is a first step toward creating a more balanced digital life.

How Social Media Affects Our Mental Health

Social media is designed to capture attention - and keep it. Each scroll, like, or comment activates emotional and cognitive processes that shape how we feel, think, and view ourselves. While some users find inspiration or connection, others experience fatigue or overstimulation.

A 2024 Pew Research Center report found that nearly half of U.S. teens are online almost constantly, with 90% using YouTube and around 60% on TikTok and Instagram. This near-constant connectivity can intensify the emotional impact of social media, affecting mood, self-esteem, and stress levels.

The outcome depends not only on how much we use these tools, but how and why. At Amae Health, clinicians note that curated content, algorithmic feeds, and alerts often reinforce habits that quietly increase stress and emotional fatigue.

How we interact with social media matters - while some people benefit from the positive effects of social media, others may experience emotional strain when usage becomes excessive.

Negative Effects of Social Media

Comparison and Low Self-Esteem

Social media often presents the highlight reel of others’ lives - filtered, polished, and carefully selected. This can trigger a subtle cycle:

Trigger → Thought → Feeling

Photo of success → "I’m falling behind" → Insecurity

Fitness transformation → "I don’t look like that" → Shame

Luxury lifestyle → "I’ll never afford this" → Hopelessness

The curated nature of platforms sets unrealistic standards. Over time, these quiet comparisons can chip away at self-worth, especially in younger users still developing their identity.

Anxiety, Stress, and Depression

The constant flow of updates, alerts, and opinions can overwhelm the mind. Research often links heavy social media use with increased emotional fatigue, particularly among adolescents. Signs of overload can include:

• Trouble focusing after long scrolling sessions
• Increased irritability or sadness after browsing
• Physical symptoms like muscle tension or rapid heartbeat
• Fatigue from endless exposure to distressing news

These are some of the most common negative effects of social media, especially when platforms are used without intention or boundaries. They often build gradually, masking their impact until they start affecting mood, relationships, and daily function.

Cyberbullying and Harassment

Toxic interactions online can leave deep emotional wounds. Unlike traditional bullying, cyberbullying can happen anytime - and often goes unnoticed by adults. In a 2023 study published in BMC Psychiatry, over 40% of adolescents reported experiencing cyberbullying, with more than 20% considering self-harm as a result.

Victims often feel trapped, fearing that speaking up might limit their internet access. The persistence and reach of online harassment make recovery more complex - especially for younger users.

Sleep Disruption and Overstimulation

Nighttime scrolling may seem harmless. But it interferes with sleep in multiple ways:

• Focus: The brain stays alert long after screen use
• Memory: Disrupted sleep impairs cognitive processing
• Mood: Poor rest can increase anxiety and reduce emotional resilience

Among the negative effects of social media, sleep interference is often overlooked - yet it plays a key role in emotional regulation and resilience. Notifications, blue light, and emotionally triggering content can delay sleep and lower its quality. Over time, this cycle contributes to brain fog, mood swings, and physical fatigue during the day.

Social Isolation and Loneliness

While social media creates the illusion of connection, it can quietly reduce meaningful offline interaction. As time spent online increases, time spent with others in person tends to decline. The result is a paradox: feeling more connected digitally while growing lonelier in daily life.

This shift affects how we form relationships, experience presence, and feel supported. For some, it replaces real-world bonding with surface-level interactions that lack emotional depth.

Positive Effects of Social Media

Connection and Community

Social media builds bridges - not just across time zones, but across life experiences.

• Close to home: A parent overseas shares bedtime stories through video calls. A friend group stays connected through group chats and shared memories.
• Beyond borders: People with rare conditions, grieving losses, or exploring identity find communities where they feel seen.

These platforms offer belonging, especially when real-world connection feels out of reach.

Access to Mental Health Resources

Another often-cited positive effect of social media is how it allows users to feel seen through shared experiences - especially when it comes to mental health. Digital spaces can offer timely, accessible mental health tools. Some of the most helpful include:

• Teletherapy platforms that bring care to your home
• Crisis text lines available 24/7 for urgent support
• YouTube channels with breathing exercises and guided meditations
• Instagram pages that normalize mental health struggles and coping tools

For many, these resources are a first step toward healing - or a bridge between therapy sessions from professional mental health clinics like Amae Health.

Education and Awareness

Social media gives people access to ideas and perspectives they may never encounter otherwise. Posts about mental health, neurodiversity, disability, and identity expand awareness beyond textbooks. By following advocates and educators, users can stay informed about social issues and health topics in real time.

• For example, one user shared they learned about their anxiety diagnosis after seeing a relatable infographic on Instagram.

Creative Expression and Inspiration

One of the most meaningful positive effects of social media is its ability to turn creativity into connection. Social media can turn quiet creativity into shared experience. It gives people space to explore and be seen.

• Art & Photography: A teen posts drawings anonymously and receives supportive comments.
• Writing & Storytelling: A blog becomes a safe place to unpack emotions and share poetry.
• Music & Humor: Short videos bring laughter and lightness into heavy days.

For many, this creative space offers not just expression - but healing.

Peer Support and Shared Experiences

Digital empathy may be one of the most overlooked yet powerful positive effects of social media. When we read someone else’s story, it can feel like looking into a mirror - and seeing ourselves more clearly. These platforms let us share challenges and celebrate progress together. They remind us we’re not the only ones navigating uncertainty.

You might find this connection through:

• Reddit threads about anxiety or ADHD
• Instagram stories on body image journeys
• YouTube vlogs about grief, recovery, or life changes

For many, these interactions feel more personal than expected - and sometimes, just as powerful as in-person support.

Why Is It Hard to Reduce Social Media Use?

As addiction expert Dr. Anna Lembke explains in The Guardian, phones function like “modern hypodermic needles” - delivering small dopamine hits with every swipe, like, or scroll. Even brief moments of boredom now trigger the urge to check a screen. But why is it so hard to stop?

Many of these features are what drive both the positive effects of social media - like connection - and the negative ones, such as dependency or distraction.

Tips for Healthy Social Media Habits

Using social media more mindfully doesn’t require quitting - just small, consistent changes. These strategies can help restore balance:

What you might try to do:

• Set daily screen limits with built-in phone tools
• Follow uplifting, educational, or inspiring content
• Schedule screen-free times - especially before bed
• Try a 1-day or weekend digital reset

What you should really avoid:

• Auto-scrolling without intention
• Following accounts that trigger comparison or stress
• Checking apps first thing in the morning
• Keeping notifications on for every app

Your habits shape your experience. When used intentionally, the positive effects of social media can take the lead, while the rest fades quietly into the background.

When Social Media Impacts Your Well-Being, Support Matters

Social media isn’t all bad or all good. For many, it’s a lifeline - for others, a source of quiet stress. The key is recognizing when it starts to affect how you feel. If you're noticing fatigue, anxiety, or self-doubt tied to your digital habits, it might be time to pause and reassess.

If the weight of online life feels too heavy, Amae Health is here to help. Our compassionate clinicians offer support that respects your experience and helps you reconnect with what matters most.

Reach out to schedule a consultation - healing starts with one conversation.

‍

Finishing a course of TMS and feeling like yourself again brings a new worry: will it hold? How long do TMS results last, and what happens if the depression comes back? The research is more encouraging than many people expect. Among people who respond to a course, roughly half to nearly two-thirds are still responding a year later, and when symptoms do return, restarting TMS brought back the improvement for most people in the research.

‍

None of that predicts any one person's course. It does show what tends to help results last, and why the months after treatment deserve a plan of their own.

What "Lasting" Means: Response vs. Remission

Two terms do most of the work in durability research. A person has responded when their depression scores fall by at least half on a standard rating scale. They're in remission when scores drop low enough that the depression is largely gone.

‍

Durability studies then ask a narrower question than the original trials did: of the people who responded or reached remission by the end of a course, how many were still doing well months later? That framing matters when you read the numbers. A result such as 62.5% of people keeping their response for a year describes people who had already responded, not everyone who started TMS. Those follow-up checks happen at set points, typically three, six, and 12 months after a course, so durability is reported as the share of people still responding at each checkpoint.

What the Research Shows About Durability

The most direct data come from a 2014 study in The Journal of Clinical Psychiatry that followed people with medication-resistant major depression for a year after they finished TMS at 42 U.S. clinical practices. Of the 257 people who completed a course and agreed to follow-up, 120 had responded or reached remission by the end of treatment. Of those 120, 75 (62.5%) kept meeting response criteria through the full 12 months.

‍

Two details shape that result. The study used a practical approach after the course: continued antidepressant medication, plus access to more TMS if symptoms returned. And over the year, 93 participants (36.2%) had TMS reintroduced at some point, averaging about 16 treatment days. So the 62.5% reflects TMS inside ongoing care, not a single course left to stand on its own.

‍

A 2019 meta-analysis in Brain Stimulation pooled 19 studies of people who had responded to a TMS course. About two-thirds were still responding at three months, about 53% at six months, and about 46% at one year. The authors' summary: roughly half of responders keep their response for up to a year after a successful course.

‍

Read together, the two studies give a realistic range of around half to nearly two-thirds of responders still doing well a year out. The other side of those numbers matters just as much. A meaningful share of people see symptoms return within the first year, and planning for that possibility is part of good care, not a sign that treatment failed.

Factors That Influence How Long Results Last

The research has identified a few patterns, mostly at the level of groups rather than individuals:

‍

• Maintenance treatment. In the 2019 meta-analysis, studies that included maintenance treatment showed higher sustained response at some time points.
• The mix of people studied. Studies with a higher proportion of women also showed higher sustained response, a group-level pattern that says nothing reliable about any one person.
• Continued medication. The best-known durability results come from people who stayed on antidepressants after TMS, so those numbers describe that combination.
• A completed course. Durability figures come from people who finished a full acute course. They don't describe what happens after a partial one.

‍

Clinicians also weigh a person's history when planning follow-up, such as how many depressive episodes they've had and how many treatments failed before TMS. The findings above don't establish how much those factors change the odds, so they inform a clinician's judgment rather than supply a number.

Maintenance TMS: What It Is and Who May Need It

TMS maintenance treatment means periodic sessions after the main course, scheduled to protect a response rather than to answer a relapse. Schedules vary between providers and between people, and no single schedule has become standard.

‍

The evidence supports the idea without settling the details. The 2019 meta-analysis found maintenance associated with more durable response, and its authors suggested maintenance be considered in practice and tested in future trials. That's a promising signal, not a proven protocol. Maintenance TMS is also separate from staying on medication: in both the year-long and six-month studies, people continued antidepressants whether or not they received more TMS.

‍

Not everyone needs it. Some people stay well for long stretches without it. Whether maintenance makes sense for a particular person is a judgment a psychiatrist makes from their history and how they're doing in the months after the course.

Can TMS Be Repeated If Symptoms Return?

Yes, and the research on restarting TMS is among the most reassuring parts of this topic. In a six-month study in Brain Stimulation, people whose depression had improved by at least a quarter with TMS stopped treatment gradually over three weeks while starting maintenance antidepressant medication. In that study, worsening had a specific meaning: a clinician-rated decline that held for two consecutive weeks, which triggered restarting TMS. Over the next 24 weeks, 38% had symptoms worsen enough to restart TMS, and 32 of those 38 people (84%) regained their improvement. Only 10% of the 99 people whose results were reported met the study's definition of relapse.

‍

A repeat course is different from maintenance. Maintenance is planned in advance to hold a response; a repeat course starts because symptoms have come back. In the year-long study described above, about a third of participants had TMS reintroduced at some point. Whether and when to restart is a decision made with a psychiatrist, based on how symptoms are changing.

What Helps Results Last Longer

Beyond maintenance and continued medication, two more things help, though neither promises that results will last for a particular person:

‍

• Catching changes early. In the six-month study, regular assessments flagged worsening symptoms, and most people who restarted TMS at that point regained their improvement.
• Staying connected to care. Therapy and regular psychiatric visits mean someone is watching for early changes between treatments.

‍

Knowing what returning depression tends to look like makes early changes easier to catch: shifts in sleep or appetite, lower energy, less interest in usual activities, and a low mood that lingers instead of lifting after a few days. When those signs show up, reaching out sooner gives a care team more options, and our guide on how to ask for help when depressed covers how to start that conversation.

‍

These describe what research associates with better long-term results in groups of patients. They aren't instructions for any one person's treatment plan; that's a psychiatrist's call, made with the whole history in view.

Talking to a Psychiatrist About a Long-Term Plan

A TMS course is the start of a plan, not the end of one. The months afterward are when follow-up, medication decisions, and a clear plan for what happens if symptoms return matter most.

‍

At Amae, TMS sits inside our integrated care model, where psychiatric care, therapy, primary care, and peer support stay linked after the course ends. We provide TMS therapy for major depressive disorder at our Los Angeles clinic and at our Bay Area clinics in Los Altos and San Mateo. Commercial insurance plans and cash pay are both accepted, and our intake team handles prior authorization. To map out what comes after a course, talk with an Amae psychiatrist about a long-term plan. Anyone in crisis can reach the 988 Suicide and Crisis Lifeline by call or text.

Frequently Asked Questions

How long do TMS results typically last?

For many people, months to a year or longer, though it varies. In a year-long study of people who responded to TMS, 62.5% kept meeting response criteria for the full 12 months. A 2019 meta-analysis found that about half of responders were still responding at one year.

What percentage of people relapse after TMS?

Some return of symptoms within a year is common. In the 2019 meta-analysis, roughly half of responders were no longer responding at one year. That isn't always a full relapse: in a six-month study, 38% had symptoms worsen enough to restart TMS, while 10% met the study's definition of relapse.

Can TMS be repeated if depression comes back?

Yes. In a six-month study, 84% of people whose symptoms worsened regained their improvement when TMS was restarted. A repeat course is different from ongoing maintenance sessions, and the decision is made with a psychiatrist based on individual history.

Do I need maintenance TMS sessions after my initial course?

Not necessarily. Some people stay well without them, and there is no standard maintenance schedule across providers. Research links maintenance with longer-lasting response, so whether it fits is a decision a psychiatrist makes based on your response and how closely symptoms are being monitored.

What can help TMS results last longer?

The research points to planned follow-up, continued medication when it's part of the plan, and catching symptom changes early. These are general findings from groups of patients, not instructions for any one person's treatment.

Is maintenance TMS covered by insurance?

It depends on the insurer and on whether sessions are billed as maintenance or as a new course for returning symptoms, since coverage can differ between the two. Ask the provider to verify benefits with your insurer before sessions begin.

‍

Citations

1. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry. 2014;75(12):1394-1401. https://pubmed.ncbi.nlm.nih.gov/25271871/
2. Senova S, Cotovio G, Pascual-Leone A, Oliveira-Maia AJ. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimulation. 2019;12(1):119-128. https://pubmed.ncbi.nlm.nih.gov/30344109/
3. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation. 2010;3(4):187-199. https://pubmed.ncbi.nlm.nih.gov/20965447/
4. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍